Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open-label study.
Daniel S PereiraKazumasa AkitaRobert B BhisitkulToshiaki NishihataYusuf AliEmiko NakamuraYoshikazu NakamuraPublished in: Eye (London, England) (2023)
Intravitreal umedaptanib pegol was safe, well tolerated, and demonstrated an indication of bioactivity in participants that have persistent subretinal fluid refractory to the treatment with anti-VEGFs.